{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-014262","form_type":"8-K","ticker":"GKOS","cik":"0001192448","company_name":"GLAUKOS Corp","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.869687+00:00","generated_at":"2026-05-30T05:48:23.069080+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Glaukos Q3 revenue $96.7M (+24% YoY), raises 2024 guidance to $377-379M","bullets":["Record Q3 net sales of $96.7M (+24% YoY); glaucoma segment $76.0M (+30%), corneal health $20.6M (+5%).","GAAP net loss narrowed to $21.4M ($0.39 loss per share) from $30.4M ($0.63) in Q3 2023.","Non-GAAP net loss $15.2M ($0.28 per share) vs $24.2M ($0.50) prior year.","Raised FY2024 net sales guidance to $377M-$379M from prior $370M-$376M.","Gross margin ~77%, non-GAAP ~82%; ended quarter with $267.2M cash."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-014262","json":"https://secwatch.observer/filing/0001558370-24-014262.json","markdown":"https://secwatch.observer/filing/0001558370-24-014262.md","text":"https://secwatch.observer/filing/0001558370-24-014262.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1192448/000155837024014262/0001558370-24-014262-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1192448/000155837024014262/gkos-20241104x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:48:23.069080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}